Imeglimin Inhibits Macrophage Foam Cell Formation and Atherosclerosis in Streptozotocin-Induced Diabetic ApoE-Deficient Mice
Cells · 2025
DOI: 10.3390/cells14070472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Ji Yeon Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon 16499, Republic of Korea. Hauptthemen laut MEDLINE: Foam Cells, Diabetes Mellitus, Experimental, Atherosclerosis, Apolipoproteins E. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of the Korean Government (MSIT).
Abstract (Originalsprache)
Atherosclerotic cardiovascular disease is a major complication of diabetes, whose progression is significantly accelerated by hyperglycemia. Imeglimin, a novel oral antidiabetic agent, has demonstrated efficacy in glucose control; however, its role in diabetes-related cardiovascular complications has not yet been fully explored. This study aimed to investigate the effects of imeglimin on foam cell formation and atherosclerosis in the context of diabetes. THP-1 macrophages were treated with oxidized low-density lipoprotein (LDL) and high glucose to induce foam cell formation in vitro. Additionally, ApoE−/− mice with streptozotocin-induced diabetes were used to determine the effects of imeglimin in vivo by analyzing metabolic parameters and atherosclerotic plaque formation. Imeglimin inhibited macrophage-derived foam cell formation by promoting the expression of ATP-binding cassette transporters (ABC) A1 and ABCG1 and downregulating the expression of CD36. The effects of imeglimin on ABCG1 and CD36 expression regulation was mediated by AMPK. In diabetic ApoE−/− mice, imeglimin reduced the atherosclerotic plaque area, decreased fasting glucose and LDL cholesterol levels, and upregulated ABCG1 expression in the liver and aorta. These findings suggest that imeglimin may have a preventive effect on foam cell formation and a therapeutic role in atherosclerosis progression in diabetic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
- Department of Physiology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
ORCID-Profile: Seung Jin Han
Förderung
- National Research Foundation of the Korean Government (MSIT)
Zitieren
APA
Lee, J. Y., Kang, Y., Jeon, J. Y., & Han, S. J. (2025). Imeglimin Inhibits Macrophage Foam Cell Formation and Atherosclerosis in Streptozotocin-Induced Diabetic ApoE-Deficient Mice. Cells. https://doi.org/10.3390/cells14070472
Vancouver
Lee JY, Kang Y, Jeon JY, Han SJ. Imeglimin Inhibits Macrophage Foam Cell Formation and Atherosclerosis in Streptozotocin-Induced Diabetic ApoE-Deficient Mice. Cells. 2025. doi:10.3390/cells14070472
BibTeX
@article{Lee2025,
author = {Lee, Ji Yeon and Kang, Yup and Jeon, Ja Young and Han, Seung Jin},
title = {Imeglimin Inhibits Macrophage Foam Cell Formation and Atherosclerosis in Streptozotocin-Induced Diabetic ApoE-Deficient Mice},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14070472}
}
EUVIMED